Change in HbA1c associated with treatment intensification among patients with type 2 diabetes and poor glycemic control

Current Medical Research and Opinion

Volumn 33, Issue 5, 2017, Pages 853-858

  Fu, Alex Z ^a   Sheehan, John J ^b,c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Glycemic control; HbA1c; treatment intensification; type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PROPENSITY SCORE; RETROSPECTIVE STUDY; CLASSIFICATION; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; MEDICATION THERAPY MANAGEMENT; ORAL DRUG ADMINISTRATION; PROCEDURES; STATISTICS AND NUMERICAL DATA; TIME TO TREATMENT; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICATION THERAPY MANAGEMENT; METFORMIN; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; TIME-TO-TREATMENT; UNITED STATES;

EID: 85014693915     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2017.1292231     Document Type: Article

References (22)

1. Fu AZ, Qiu Y, Radican L, et al. Impact of concurrent macrovascular co-morbidities on healthcare utilization in patients with type 2 diabetes in Europe:a matched study. Diabetes Obes Metab 2010;12:631-7
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015:a patient-centered approach:update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
3. Fowler MJ., Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008;26:77-82
4. Fu AZ, Qiu Y, Radican L, Luo N., Marginal differences in health-related quality of life of diabetic patients with and without macrovascular comorbid conditions in the United States. Qual Life Res 2011;20:825-32
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21:438-47
6. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19:327-36
7. McCoy RG, Zhang Y, Herrin J, et al. Changing trends in type 2 diabetes mellitus treatment intensification, 2002–2010. Am J Manag Care 2015;21:e288-96
8. Lin J, Zhou S, Wei W, et al. Does clinical inertia vary by personalized a1c goal? A study of predictors and prevalence of clinical inertia in a U.S. managed-care setting. Endocr Pract 2016;22:151-61
9. Fu AZ, Qiu Y, Davies MJ, et al. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diabetes Obes Metab 2011;13:765-9
10. Fu AZ, Sheehan J., Treatment intensification for patients with type 2 diabetes and poor glycemic control. Diabetes Obes Metab 2016;18:892-8
11. Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol 2015;14:100
12. Fu AZ, Qiu Y, Radican L, et al. Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe:a matched cohort study. Cardiovasc Diabetol 2010;9:15
13. Hansen LG, Chang S., Health Research Data for the Real World:The MarketScan Databases. White paper. 2011 http://truvenhealth.com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf
14. Quint JB., Health Research Data for the Real World:The MarketScan Databases. White paper. Truven Health Analytics, 2015 http://truvenhealth.com/markets/life-sciences/products/data-tools/marketscan-databases
15. National Quality Forum. Adding Value to Diabetes Quality Measures:Opportunities and Methodological Challenges. National Quality Forum 2015 http://www.qualityforum.org/Publications/2008/11/White_Paper,_Adding_Value_to_Diabetes_Quality_Measures__Opportunities_and_Methodological_Challenges.aspx
16. Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15-23
17. Deyo RA, Cherkin DC, Ciol MA., Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
18. Parsons LS., Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. SAS Users Group International (SUGI) 26th conference. Paper 214–26. 2001
19. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825-34
20. Romanelli RJ, Chung S, Pu J, et al. Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2015;108:170-8
21. Rajpathak SN, Rajgopalan S, Engel SS., Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy. J Diabetes Complications 2014;28:831-5
22. Levin PA, Wei W, Zhou S, et al. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes. J Manag Care Spec Pharm 2014;20:501-12